Zoticon BioVentures

Zoticon has invested over $100 million to date in promising phase III therapeutics including two oncology products and a cardiovascular.

Bet Shemesh Jerusalem District (HQ)

http://zoticon.com

Tech stackLearn more about the technologies and tools that this company uses.

Sopherion Therapeutics